menu
    • menu

    Find Dihydroergocryptine manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    1

    API Suppliers

    API Suppliers

    0

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    1

    NDC API

    NDC API

    0

    VMF

    NDC API

    1

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 81

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    1

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    1

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    0

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    72 RELATED EXCIPIENT COMPANIES

    145EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Dihydro-alpha-ergocryptine, 25447-66-9, Alpha-dihydroergocryptine, 9,10-dihydro-alpha-ergocryptine, Alpha-dihydroergocriptine, 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-9,10alpha-dihydroergotaman-3',6',18-trione
    Molecular Formula
    C32H43N5O5
    Molecular Weight
    577.7  g/mol
    InChI Key
    PBUNVLRHZGSROC-VTIMJTGVSA-N
    FDA UNII
    202229IR8Y
    Dihydroergocryptine
    A 9,10alpha-dihydro derivative of ERGOTAMINE that contains an isopropyl sidechain at the 2' position and an alpha-isobutyl sidechain at 5'alpha position of the molecule.
    1 2D Structure

    Dihydroergocryptine

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (6aR,9R,10aR)-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
    2.1.2 InChI
    InChI=1S/C32H43N5O5/c1-17(2)12-25-29(39)36-11-7-10-26(36)32(41)37(25)30(40)31(42-32,18(3)4)34-28(38)20-13-22-21-8-6-9-23-27(21)19(15-33-23)14-24(22)35(5)16-20/h6,8-9,15,17-18,20,22,24-26,33,41H,7,10-14,16H2,1-5H3,(H,34,38)/t20-,22-,24-,25+,26+,31-,32+/m1/s1
    2.1.3 InChI Key
    PBUNVLRHZGSROC-VTIMJTGVSA-N
    2.1.4 Canonical SMILES
    CC(C)CC1C(=O)N2CCCC2C3(N1C(=O)C(O3)(C(C)C)NC(=O)C4CC5C(CC6=CNC7=CC=CC5=C67)N(C4)C)O
    2.1.5 Isomeric SMILES
    CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@@H]4C[C@H]5[C@@H](CC6=CNC7=CC=CC5=C67)N(C4)C)O
    2.2 Other Identifiers
    2.2.1 UNII
    202229IR8Y
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Almirid

    2. Cripar

    3. Dihydroergocryptine Mesylate

    4. Dihydroergocryptine Monomesylate

    5. Dihydroergokryptine Mesylate

    6. Dihydroergokryptine Monomesylate

    7. Mesylate, Dihydroergocryptine

    8. Mesylate, Dihydroergokryptine

    9. Monomesylate, Dihydroergocryptine

    10. Monomesylate, Dihydroergokryptine

    2.3.2 Depositor-Supplied Synonyms

    1. Dihydro-alpha-ergocryptine

    2. 25447-66-9

    3. Alpha-dihydroergocryptine

    4. 9,10-dihydro-alpha-ergocryptine

    5. Alpha-dihydroergocriptine

    6. 12'-hydroxy-2'-(1-methylethyl)-5'alpha-(2-methylpropyl)-9,10alpha-dihydroergotaman-3',6',18-trione

    7. Chembl1743263

    8. Chebi:59919

    9. 202229ir8y

    10. Dihydroergocriptine

    11. (10alphah)-12'-hydroxy-5'alpha-(2-methylpropyl)-3',6',18-trioxo-2'-(propan-2-yl)-9,10-dihydroergotaman

    12. (6ar,9r,10ar)-n-[(1s,2s,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide

    13. 9,10-dihydroergocryptine

    14. Einecs 246-993-6

    15. Dihydro-.alpha.-ergocryptine

    16. Unii-202229ir8y

    17. Ncgc00183332-01

    18. Dsstox_cid_28615

    19. Dsstox_rid_82885

    20. Dsstox_gsid_48689

    21. Schembl233373

    22. Dtxsid5048689

    23. Bdbm81453

    24. Zinc3929793

    25. Tox21_113078

    26. Bdbm50390994

    27. Pdsp2_001088

    28. Cas_159729

    29. Db11274

    30. Nsc_159729

    31. Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'.alpha.,10.alpha.)-

    32. Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-, (5'alpha,10alpha)-

    33. Cas-25447-66-9

    34. D07835

    35. Q905717

    36. (6ar,9r,10ar)-n-[(1s,2r,4r,7s)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-propan-2-yl-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide

    37. 12'-hydroxy-2'-(1-methylethyl)-5'.alpha.-(2-methylpropyl)-9,10.alpha.-dihydroergotaman-3',6',18-trione

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 577.7 g/mol
    Molecular Formula C32H43N5O5
    XLogP33.1
    Hydrogen Bond Donor Count3
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count5
    Exact Mass577.32641949 g/mol
    Monoisotopic Mass577.32641949 g/mol
    Topological Polar Surface Area118 Ų
    Heavy Atom Count42
    Formal Charge0
    Complexity1130
    Isotope Atom Count0
    Defined Atom Stereocenter Count7
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Alpha-dihydroergocryptine has been studied for the early treatment of Parkinson disease as well as for its use in migraine prophylaxis, treatment of low blood pressure and peripheral vascular disorder. To know more about the ergoloid mesylate mixture and its uses please visit [DB01049].

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    The effect of alpha-dihydroergocryptine in dopamine receptors was tested in PD patients and seem to generate a significant clinical improvement in the tested patients as well as to reduce motor complications and side effects. In long-term clinical trials with Parkinson disease patients, the administration of alpha-dihydroergocryptine and levodopa, the symptoms were reposted to improve or completely vanish in 80% of the tested individuals. All the registered effects of alpha-dihydroergocryptine suggest a potential neuroprotective effect of this drug and some reports have indicated that this activity may be related to the activation of NF-kB. The effect of alpha-dihydroergocryptine in the dopamine D2 receptor also reduces prolactin plasma levels and induce hypotension. To know more about the ergoloid mesylate mixture please visit [DB01049].

    5.2 MeSH Pharmacological Classification

    Dopamine Agonists

    Drugs that bind to and activate dopamine receptors. (See all compounds classified as Dopamine Agonists.)

    Vasodilator Agents

    Drugs used to cause dilation of the blood vessels. (See all compounds classified as Vasodilator Agents.)

    5.3 Absorption, Distribution and Excretion

    Absorption

    Alpha-dihydroergocryptine is rapidly absorbed but it presents a very low bioavailability as it is part of a first-pass hepatic metabolism and thus less of 5% of the administered dose reaches blood circulation. The peak plasma concentration is attained after 30-120 minutes. The absorption of alpha-dihydroergocryptine is not affected by the co-administration with food. When administered in repeated oral doses the Cmax after 1 hour was registered to be 2157 pg/ml. To know more about the ergoloid mesylate mixture please visit [DB01049].

    Route of Elimination

    Alpha-dihydroergocryptine is eliminated mainly by feces and to present a very low urinary excretion. To know more about the ergoloid mesylate mixture please visit [DB01049].

    Volume of Distribution

    In preclinical studies, the volume of distribution after intravenous or oral administration was registered to be 11.054 L and 218.630 L respectively. To know more about the ergoloid mesylate mixture please visit [DB01049].

    Clearance

    In preclinical studies, the clearance rate after intravenous or oral administration was registered to be 1.129 L/h and 25.98 L/h respectively. To know more about the ergoloid mesylate mixture please visit [DB01049].

    5.4 Metabolism/Metabolites

    Alpha-dihydroergocryptine presents a linear metabolism with the formation of active metabolites and the metabolism kinetics of this compound has no interference with L-dopa. It is highly metabolized with a rate of 2.4 ng/min/mg protein in the microsomal system and a formation of eight different metabolites. the metabolism of alpha-dihydroergocryptine seems to be highly marked by the action of CYP 3A4. To know more about the ergoloid mesylate mixture please visit [DB01049].

    5.5 Biological Half-Life

    Alpha-dihydroergocryptine has been studied in Parkinson disease models and it has shown a half-life of 12-16 hours. To know more about the ergoloid mesylate mixture please visit [DB01049].

    5.6 Mechanism of Action

    Alpha-dihydroergocryptine is an established high-affinity ligand to alpha 1 and alpha 2 adrenoreceptors in a number of tissues as well as a dopamine ligand in the brain. It is reported to be a potent agonist of the dopamine D2 receptor and a partial agonist of the dopamine receptors D1 and D3. To know more about the ergoloid mesylate mixture please visit [DB01049] and to know more about the isomer please visit [DB11275].

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Granulation

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Topical

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    ABOUT THIS PAGE

    Dihydroergocryptine Manufacturers

    A Dihydroergocryptine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dihydroergocryptine, including repackagers and relabelers. The FDA regulates Dihydroergocryptine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dihydroergocryptine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Dihydroergocryptine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Dihydroergocryptine Suppliers

    A Dihydroergocryptine supplier is an individual or a company that provides Dihydroergocryptine active pharmaceutical ingredient (API) or Dihydroergocryptine finished formulations upon request. The Dihydroergocryptine suppliers may include Dihydroergocryptine API manufacturers, exporters, distributors and traders.

    click here to find a list of Dihydroergocryptine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Dihydroergocryptine NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dihydroergocryptine as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Dihydroergocryptine API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Dihydroergocryptine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Dihydroergocryptine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dihydroergocryptine NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Dihydroergocryptine suppliers with NDC on PharmaCompass.

    Dihydroergocryptine GMP

    Dihydroergocryptine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Dihydroergocryptine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dihydroergocryptine GMP manufacturer or Dihydroergocryptine GMP API supplier for your needs.

    Dihydroergocryptine CoA

    A Dihydroergocryptine CoA (Certificate of Analysis) is a formal document that attests to Dihydroergocryptine's compliance with Dihydroergocryptine specifications and serves as a tool for batch-level quality control.

    Dihydroergocryptine CoA mostly includes findings from lab analyses of a specific batch. For each Dihydroergocryptine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Dihydroergocryptine may be tested according to a variety of international standards, such as European Pharmacopoeia (Dihydroergocryptine EP), Dihydroergocryptine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dihydroergocryptine USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search